{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:39:58Z","timestamp":1793039998700,"version":"4.5.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01691-2","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T17:45:02Z","timestamp":1753033502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Oncolytic virotherapy and tumor microenvironment modulation"],"prefix":"10.1007","volume":"25","author":[{"given":"Sebasti\u00e1n","family":"Rivera-Orellana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhommara","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Palacios-Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Ojeda-Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Altamirano-Colina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Alcocer-Veintimilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Parrales-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Izquierdo-Condoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"V\u00e1sconez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Ortiz-Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Muslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"1691_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.omto.2023.07.006","volume":"30","author":"J Hedberg","year":"2023","unstructured":"Hedberg J, et al. Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution. Mol Ther Oncolytics. 2023;30:39\u201355.","journal-title":"Mol Ther Oncolytics"},{"key":"1691_CR2","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","volume":"16","author":"M Mondal","year":"2020","unstructured":"Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020;16:2389\u2013402.","journal-title":"Hum Vaccin Immunother"},{"key":"1691_CR3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler SE, Speranza M-C, Cho C-F, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3:841\u20139.","journal-title":"JAMA Oncol"},{"key":"1691_CR4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373\u20139.","journal-title":"Cancer Sci"},{"key":"1691_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","volume":"18","author":"PK Bommareddy","year":"2017","unstructured":"Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18:1\u201315.","journal-title":"Am J Clin Dermatol"},{"key":"1691_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/psp4.12898","volume":"12","author":"M Ahamadi","year":"2023","unstructured":"Ahamadi M, et al. Oncolytic viral kinetics mechanistic modeling of talimogene laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. CPT Pharmacomet Syst Pharmacol. 2023;12:250\u201360.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1691_CR7","volume":"5","author":"J Pol","year":"2016","unstructured":"Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5: e1115641.","journal-title":"Oncoimmunology"},{"key":"1691_CR8","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1634\/theoncologist.2019-0438","volume":"25","author":"O Hamid","year":"2020","unstructured":"Hamid O, Ismail R, Puzanov I. Intratumoral immunotherapy-update 2019. Oncologist. 2020;25:e423\u201338.","journal-title":"Oncologist"},{"key":"1691_CR9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/imt.15.116","volume":"8","author":"R Coffin","year":"2016","unstructured":"Coffin R. Interview with Robert coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer. Immunotherapy. 2016;8:103\u20136.","journal-title":"Immunotherapy"},{"key":"1691_CR10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney JA, et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41:528\u201340.","journal-title":"J Clin Oncol"},{"key":"1691_CR11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2023.6.JNS23243","volume":"140","author":"R Reddy","year":"2024","unstructured":"Reddy R, et al. Oncolytic viral therapy: a review and promising future directions. J Neurosurg. 2024;140:319\u201327.","journal-title":"J Neurosurg"},{"key":"1691_CR12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","volume":"7","author":"S Thomas","year":"2019","unstructured":"Thomas S, et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer. 2019;7:214.","journal-title":"J Immunother Cancer"},{"key":"1691_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.105164","volume":"160","author":"N Haghighi-Najafabadi","year":"2021","unstructured":"Haghighi-Najafabadi N, Roohvand F, Shams Nosrati MS, Teimoori-Toolabi L, Azadmanesh K. Oncolytic herpes simplex virus type-1 expressing IL-12 efficiently replicates and kills human colorectal cancer cells. Microb Pathog. 2021;160: 105164.","journal-title":"Microb Pathog"},{"key":"1691_CR14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.187.3.341","volume":"187","author":"K Goldsmith","year":"1998","unstructured":"Goldsmith K, Chen W, Johnson DC, Hendricks RL. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J Exp Med. 1998;187:341\u20138.","journal-title":"J Exp Med"},{"key":"1691_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jdermsci.2007.12.001","volume":"50","author":"D Watanabe","year":"2008","unstructured":"Watanabe D, et al. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci. 2008;50:185\u201396.","journal-title":"J Dermatol Sci"},{"key":"1691_CR16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.omto.2020.12.007","volume":"20","author":"G Takano","year":"2021","unstructured":"Takano G, et al. Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma. Mol Ther Oncolytics. 2021;20:220\u20137.","journal-title":"Mol Ther Oncolytics"},{"key":"1691_CR17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ijc.33550","volume":"149","author":"IR Eissa","year":"2021","unstructured":"Eissa IR, et al. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment. Int J Cancer. 2021;149:214\u201327.","journal-title":"Int J Cancer"},{"key":"1691_CR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fonc.2017.00149","volume":"7","author":"IR Eissa","year":"2017","unstructured":"Eissa IR, et al. Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials. Front Oncol. 2017;7:149.","journal-title":"Front Oncol"},{"key":"1691_CR19","doi-asserted-by":"crossref","first-page":"21570","DOI":"10.1038\/s41598-022-25065-w","volume":"12","author":"M Abdelmoneim","year":"2022","unstructured":"Abdelmoneim M, et al. Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model. Sci Rep. 2022;12:21570.","journal-title":"Sci Rep"},{"key":"1691_CR20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.31083\/j.fbl2705151","volume":"27","author":"J Ripp","year":"2022","unstructured":"Ripp J, Hentzen S, Saeed A. Oncolytic viruses as an adjunct to immune checkpoint inhibition. Front Biosci. 2022;27:151.","journal-title":"Front Biosci"},{"key":"1691_CR21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.gt.3301664","volume":"9","author":"V Papanastassiou","year":"2002","unstructured":"Papanastassiou V, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 2002;9:398\u2013406.","journal-title":"Gene Ther"},{"key":"1691_CR22","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-16-2900","volume":"23","author":"KA Streby","year":"2017","unstructured":"Streby KA, et al. Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res. 2017;23:3566\u201374.","journal-title":"Clin Cancer Res"},{"key":"1691_CR23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/v15030603","volume":"15","author":"S Tazzyman","year":"2023","unstructured":"Tazzyman S, et al. HSV1716 prevents myeloma cell regrowth when combined with Bortezomib in vitro and significantly reduces systemic tumor growth in mouse models. Viruses. 2023;15:603.","journal-title":"Viruses"},{"key":"1691_CR24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","volume":"150","author":"SJ Danson","year":"2020","unstructured":"Danson SJ, et al. Oncolytic herpesvirus therapy for mesothelioma - A phase I\/IIa trial of intrapleural administration of HSV1716. Lung Cancer. 2020;150:145\u201351.","journal-title":"Lung Cancer"},{"key":"1691_CR25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-023-02309-4","volume":"29","author":"H Soliman","year":"2023","unstructured":"Soliman H, et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023;29:450\u20137.","journal-title":"Nat Med"},{"key":"1691_CR26","doi-asserted-by":"crossref","first-page":"7679","DOI":"10.3390\/molecules28227679","volume":"28","author":"H Li","year":"2023","unstructured":"Li H, et al. Joining forces: the combined application of therapeutic viruses and nanomaterials in cancer therapy. Molecules. 2023;28:7679.","journal-title":"Molecules"},{"key":"1691_CR27","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ejca.2018.01.012","volume":"92","author":"H Al-Janabi","year":"2018","unstructured":"Al-Janabi H, Conner J, Taher Z, Staniland S, Muthana M. Breast cancer immunotherapy using magnetised oncolytic viruses. Eur J Cancer. 2018;92:S4.","journal-title":"Eur J Cancer"},{"key":"1691_CR28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/14712598.2011.558838","volume":"11","author":"K Guse","year":"2011","unstructured":"Guse K, Cerullo V, Hemminki A. Oncolytic vaccinia virus for the treatment of cancer. Expert Opin Biol Ther. 2011;11:595\u2013608.","journal-title":"Expert Opin Biol Ther"},{"key":"1691_CR29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40164-022-00338-2","volume":"11","author":"S Cousin","year":"2022","unstructured":"Cousin S, et al. Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer. Exp Hematol Oncol. 2022;11:104.","journal-title":"Exp Hematol Oncol"},{"key":"1691_CR30","doi-asserted-by":"crossref","first-page":"e006024","DOI":"10.1136\/jitc-2022-006024","volume":"11","author":"N Lee","year":"2023","unstructured":"Lee N, et al. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies. J Immunother Cancer. 2023;11:e006024.","journal-title":"J Immunother Cancer"},{"key":"1691_CR31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/mt.2011.276","volume":"20","author":"KA Parato","year":"2012","unstructured":"Parato KA, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2012;20:749\u201358.","journal-title":"Mol Ther"},{"key":"1691_CR32","first-page":"646","volume":"20","author":"M Li","year":"2023","unstructured":"Li M, Zhang M, Ye Q, Liu Y, Qian W. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review. Cancer Biol Med. 2023;20:646\u201361.","journal-title":"Cancer Biol Med"},{"key":"1691_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.16.608170","author":"SJ Komant","year":"2024","unstructured":"Komant SJ, et al. Oncolytic vaccinia virus as a precision cancer vaccine platform. BioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.08.16.608170.","journal-title":"BioRxiv"},{"key":"1691_CR34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-398342-8.00008-2","volume":"115","author":"V Cerullo","year":"2012","unstructured":"Cerullo V, Koski A, V\u00e4h\u00e4-Koskela M, Hemminki A. Chapter eight\u2013Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res. 2012;115:265\u2013318.","journal-title":"Adv Cancer Res"},{"key":"1691_CR35","volume":"579","author":"A-R Yoon","year":"2023","unstructured":"Yoon A-R, et al. Oncolytic adenovirus as pancreatic cancer-targeted therapy: where do we go from here? Cancer Lett. 2023;579: 216456.","journal-title":"Cancer Lett"},{"key":"1691_CR36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nbt0411-295","volume":"29","author":"C Schmidt","year":"2011","unstructured":"Schmidt C. Amgen spikes interest in live virus vaccines for hard-to-treat cancers. Nat Biotechnol. 2011;29:295\u20136.","journal-title":"Nat Biotechnol"},{"key":"1691_CR37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trsl.2021.04.008","volume":"237","author":"N Abd-Aziz","year":"2021","unstructured":"Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Transl Res. 2021;237:98\u2013123.","journal-title":"Transl Res"},{"key":"1691_CR38","first-page":"764","volume":"62","author":"B Geoerger","year":"2002","unstructured":"Geoerger B, et al. Oncolytic activity of the E1B\u201355 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 2002;62:764\u201372.","journal-title":"Cancer Res"},{"key":"1691_CR39","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.addr.2011.12.011","volume":"64","author":"J-W Choi","year":"2012","unstructured":"Choi J-W, Lee J-S, Kim SW, Yun C-O. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev. 2012;64:720\u20139.","journal-title":"Adv Drug Deliv Rev"},{"key":"1691_CR40","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jat.4408","volume":"43","author":"A Rasa","year":"2023","unstructured":"Rasa A, Alberts P. Oncolytic virus preclinical toxicology studies. J Appl Toxicol. 2023;43:620\u201348.","journal-title":"J Appl Toxicol"},{"key":"1691_CR41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.772659","volume":"12","author":"ST Tseha","year":"2022","unstructured":"Tseha ST. Role of adenoviruses in cancer therapy. Front Oncol. 2022;12: 772659.","journal-title":"Front Oncol"},{"key":"1691_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"M Liang","year":"2018","unstructured":"Liang M. Oncorine, the world first oncolytic virus medicine and its update in china. Curr Cancer Drug Targets. 2018;18:171\u20136.","journal-title":"Curr Cancer Drug Targets"},{"key":"1691_CR43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3892\/or.2020.7841","volume":"45","author":"L Zhang","year":"2021","unstructured":"Zhang L, et al. S100A8 promotes chemoresistance via augmenting autophagy in B-cell lymphoma cells. Oncol Rep. 2021;45:151\u20138.","journal-title":"Oncol Rep"},{"key":"1691_CR44","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100639","volume":"45","author":"NH Goradel","year":"2021","unstructured":"Goradel NH, et al. Oncolytic virotherapy: challenges and solutions. Curr Probl Cancer. 2021;45: 100639.","journal-title":"Curr Probl Cancer"},{"key":"1691_CR45","first-page":"304","volume":"5","author":"F Warricker","year":"2021","unstructured":"Warricker F, Khakoo SI, Blunt MD. The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. J Transl Genet Genom. 2021;5:304\u201322.","journal-title":"J Transl Genet Genom"},{"key":"1691_CR46","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.ymthe.2024.04.029","volume":"32","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study. Mol Ther. 2024;32:2000\u201320.","journal-title":"Mol Ther"},{"key":"1691_CR47","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/1078-0432.CCR-24-1126","volume":"30","author":"N Silva-Pilipich","year":"2024","unstructured":"Silva-Pilipich N, Smerdou C. A dual-armed oncolytic virus shows clinical efficacy in advanced solid cancers. Clin Cancer Res. 2024;30:3649\u201351.","journal-title":"Clin Cancer Res"},{"key":"1691_CR48","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8:156.","journal-title":"Signal Transduct Target Ther"},{"key":"1691_CR49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.crstbi.2022.01.001","volume":"4","author":"N Sharma","year":"2022","unstructured":"Sharma N, Gadhave K, Kumar P, Giri R. Transactivation domain of adenovirus early region 1A (E1A): investigating folding dynamics and aggregation. Curr Res Struct Biol. 2022;4:29\u201340.","journal-title":"Curr Res Struct Biol"},{"key":"1691_CR50","doi-asserted-by":"crossref","first-page":"773","DOI":"10.21873\/anticanres.14829","volume":"41","author":"F Sakurai","year":"2021","unstructured":"Sakurai F, Nishimae F, Takayama K, Mizuguchi H. Optimization of an E1A gene expression cassette in an oncolytic adenovirus for efficient tumor cell killing activity. Anticancer Res. 2021;41:773\u201382.","journal-title":"Anticancer Res"},{"key":"1691_CR51","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1172\/JCI9871","volume":"105","author":"KL Norman","year":"2000","unstructured":"Norman KL, Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest. 2000;105:1035\u20138.","journal-title":"J Clin Invest"},{"key":"1691_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01937-19","author":"A Mohamed","year":"2020","unstructured":"Mohamed A, Smiley JR, Shmulevitz M. Polymorphisms in the most oncolytic reovirus strain confer enhanced cell attachment, transcription, and single-step replication kinetics. J Virol. 2020. https:\/\/doi.org\/10.1128\/JVI.01937-19.","journal-title":"J Virol"},{"key":"1691_CR53","volume":"960","author":"S-M Seyed-Khorrami","year":"2023","unstructured":"Seyed-Khorrami S-M, et al. A promising future in cancer immunotherapy: oncolytic viruses. Eur J Pharmacol. 2023;960: 176063.","journal-title":"Eur J Pharmacol"},{"key":"1691_CR54","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10637-009-9279-8","volume":"28","author":"R Gollamudi","year":"2010","unstructured":"Gollamudi R, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs. 2010;28:641\u20139.","journal-title":"Invest New Drugs"},{"key":"1691_CR55","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108193","volume":"239","author":"G Ghajar-Rahimi","year":"2022","unstructured":"Ghajar-Rahimi G, et al. Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacol Ther. 2022;239: 108193.","journal-title":"Pharmacol Ther"},{"key":"1691_CR56","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3390\/biomedicines9040419","volume":"9","author":"S Chaurasiya","year":"2021","unstructured":"Chaurasiya S, Fong Y, Warner SG. Oncolytic virotherapy for cancer: clinical experience. Biomedicines. 2021;9:419.","journal-title":"Biomedicines"},{"key":"1691_CR57","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2017.07.135","volume":"146","author":"DE Cohn","year":"2017","unstructured":"Cohn DE, et al. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin\u00ae) in recurrent ovarian, tubal, or peritoneal cancer: an NRG oncology\/gynecologic oncology group study. Gynecol Oncol. 2017;146:477\u201383.","journal-title":"Gynecol Oncol"},{"key":"1691_CR58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0733-8635(01)00002-X","volume":"20","author":"JR Stalkup","year":"2002","unstructured":"Stalkup JR. A review of measles virus. Dermatol Clin. 2002;20:209\u201315.","journal-title":"Dermatol Clin"},{"key":"1691_CR59","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.3390\/v14122641","volume":"14","author":"L Amurri","year":"2022","unstructured":"Amurri L, Reynard O, Gerlier D, Horvat B, Iampietro M. Measles virus-induced host immunity and mechanisms of viral evasion. Viruses. 2022;14:2641.","journal-title":"Viruses"},{"key":"1691_CR60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41420-023-01466-2","volume":"9","author":"A Wu","year":"2023","unstructured":"Wu A, et al. Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3\/GSDME-mediated pyroptosis. Cell Death Discov. 2023;9:171.","journal-title":"Cell Death Discov"},{"key":"1691_CR61","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","volume":"15","author":"E Galanis","year":"2024","unstructured":"Galanis E, et al. Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial. Nat Commun. 2024;15:493.","journal-title":"Nat Commun"},{"key":"1691_CR62","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.ymthe.2006.08.352","volume":"13","author":"RM Myers","year":"2006","unstructured":"Myers RM, et al. 297 Safety of repeat intracerebral administration of MV-CEA in Rhesus macaques in support of a phase I\/II clinical trial for patients with recurrent gliomas. Mol Ther. 2006;13:S113.","journal-title":"Mol Ther"},{"key":"1691_CR63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","volume":"184","author":"K Ganar","year":"2014","unstructured":"Ganar K, Das M, Sinha S, Kumar S. Newcastle disease virus: current status and our understanding. Virus Res. 2014;184:71\u201381.","journal-title":"Virus Res"},{"key":"1691_CR64","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/biomedicines10030562","volume":"10","author":"V Schirrmacher","year":"2022","unstructured":"Schirrmacher V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines. 2022;10:562.","journal-title":"Biomedicines"},{"key":"1691_CR65","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-020-02495-x","volume":"69","author":"S Burke","year":"2020","unstructured":"Burke S, et al. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer Immunol Immunother. 2020;69:1015\u201327.","journal-title":"Cancer Immunol Immunother"},{"key":"1691_CR66","doi-asserted-by":"crossref","first-page":"1325558","DOI":"10.3389\/fmicb.2024.1325558","volume":"15","author":"LA Santry","year":"2024","unstructured":"Santry LA, et al. Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer. Front Microbiol. 2024;15:1325558.","journal-title":"Front Microbiol"},{"key":"1691_CR67","doi-asserted-by":"crossref","first-page":"1172292","DOI":"10.3389\/fonc.2023.1172292","volume":"13","author":"L Zhu","year":"2023","unstructured":"Zhu L, et al. Recent advances in oncolytic virus therapy for hepatocellular carcinoma. Front Oncol. 2023;13:1172292.","journal-title":"Front Oncol"},{"key":"1691_CR68","volume":"289","author":"L Fan","year":"2024","unstructured":"Fan L, et al. Newcastle disease virus activates the PI3K\/AKT signaling pathway by targeting PHLPP2 degradation to delay cell apoptosis and promote viral replication. Vet Microbiol. 2024;289: 109949.","journal-title":"Vet Microbiol"},{"key":"1691_CR69","doi-asserted-by":"crossref","first-page":"23869","DOI":"10.1073\/pnas.2007773117","volume":"117","author":"Z He","year":"2020","unstructured":"He Z, et al. Neural progenitor cell pyroptosis contributes to Zika virus-induced brain atrophy and represents a therapeutic target. Proc Natl Acad Sci USA. 2020;117:23869\u201378.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1691_CR70","doi-asserted-by":"crossref","first-page":"7344","DOI":"10.1038\/s41467-023-42985-x","volume":"14","author":"S Goellner","year":"2023","unstructured":"Goellner S, et al. Zika virus prM protein contains cholesterol binding motifs required for virus entry and assembly. Nat Commun. 2023;14:7344.","journal-title":"Nat Commun"},{"key":"1691_CR71","doi-asserted-by":"crossref","first-page":"14487","DOI":"10.3390\/ijms241914487","volume":"24","author":"V Grunwald","year":"2023","unstructured":"Grunwald V, et al. Development of zika virus E variants for pseudotyping retroviral vectors targeting glioblastoma cells. Int J Mol Sci. 2023;24:14487.","journal-title":"Int J Mol Sci"},{"key":"1691_CR72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ymthe.2024.01.006","volume":"32","author":"GM Novaes","year":"2024","unstructured":"Novaes GM, et al. Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors. Mol Ther. 2024;32:440\u201356.","journal-title":"Mol Ther"},{"key":"1691_CR73","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115094","volume":"98","author":"E Ortiz-Prado","year":"2020","unstructured":"Ortiz-Prado E, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020;98: 115094.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1691_CR74","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.833174","volume":"13","author":"A L\u00f3pez-Cort\u00e9s","year":"2022","unstructured":"L\u00f3pez-Cort\u00e9s A, et al. Pulmonary inflammatory response in lethal COVID-19 reveals potential therapeutic targets and drugs in phases III\/IV clinical trials. Front Pharmacol. 2022;13: 833174.","journal-title":"Front Pharmacol"},{"key":"1691_CR75","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.598925","volume":"12","author":"A L\u00f3pez-Cort\u00e9s","year":"2021","unstructured":"L\u00f3pez-Cort\u00e9s A, et al. In silico analyses of immune system protein interactome network, single-cell RNA sequencing of human tissues, and artificial neural networks reveal potential therapeutic targets for drug repurposing against COVID-19. Front Pharmacol. 2021;12: 598925.","journal-title":"Front Pharmacol"},{"key":"1691_CR76","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis NC, L\u00f3pez-Cort\u00e9s A, Gonz\u00e1lez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccin. 2021;6:28.","journal-title":"NPJ Vaccin"},{"key":"1691_CR77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279578","volume":"18","author":"OK Choong","year":"2023","unstructured":"Choong OK, et al. SARS-CoV-2 replicates and displays oncolytic properties in clear cell and papillary renal cell carcinoma. PLoS ONE. 2023;18: e0279578.","journal-title":"PLoS ONE"},{"key":"1691_CR78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.552909","volume":"11","author":"Z Abdelrahman","year":"2020","unstructured":"Abdelrahman Z, Li M, Wang X. Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Front Immunol. 2020;11: 552909.","journal-title":"Front Immunol"},{"key":"1691_CR79","doi-asserted-by":"crossref","first-page":"1082191","DOI":"10.3389\/fimmu.2023.1082191","volume":"14","author":"AA Alkayyal","year":"2023","unstructured":"Alkayyal AA, et al. SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus. Front Immunol. 2023;14:1082191.","journal-title":"Front Immunol"},{"key":"1691_CR80","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.3390\/cancers14225648","volume":"14","author":"M Sheinin","year":"2022","unstructured":"Sheinin M, Jeong B, Paidi RK, Pahan K. Regression of lung cancer in mice by intranasal administration of SARS-CoV-2 Spike S1. Cancers. 2022;14:5648.","journal-title":"Cancers"},{"key":"1691_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000878corr1","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, et al. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000878corr1.","journal-title":"J Immunother Cancer"},{"key":"1691_CR82","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/ijms24032326","volume":"24","author":"JP Bounassar-Filho","year":"2023","unstructured":"Bounassar-Filho JP, Boeckler-Troncoso L, Cajigas-Gonzalez J, Zavala-Cerna MG. SARS-CoV-2 as an oncolytic virus following reactivation of the immune system: a review. Int J Mol Sci. 2023;24:2326.","journal-title":"Int J Mol Sci"},{"key":"1691_CR83","doi-asserted-by":"publisher","unstructured":"Oxford textbook of cancer biology. (Oxford University Press, 2019). https:\/\/doi.org\/10.1093\/med\/9780198779452.001.0001.","DOI":"10.1093\/med\/9780198779452.001.0001"},{"key":"1691_CR84","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","volume":"9","author":"G Marelli","year":"2018","unstructured":"Marelli G, Howells A, Lemoine NR, Wang Y. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Front Immunol. 2018;9:866.","journal-title":"Front Immunol"},{"key":"1691_CR85","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3332\/ecancer.2020.1149","volume":"14","author":"V Martini","year":"2020","unstructured":"Martini V, et al. Oncolytic virotherapy: new weapon for breast cancer treatment. Ecancermedicalscience. 2020;14:1149.","journal-title":"Ecancermedicalscience"},{"key":"1691_CR86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cdd.2011.96","volume":"19","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, et al. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012. Cell Death Differ. 2012;19:107\u201320.","journal-title":"Cell Death Differ"},{"key":"1691_CR87","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pathol-052016-100247","volume":"12","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Kepp O, Chan FK-M, Kroemer G. Necroptosis: mechanisms and relevance to disease. Annu Rev Pathol. 2017;12:103\u201330.","journal-title":"Annu Rev Pathol"},{"key":"1691_CR88","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrm.2016.149","volume":"18","author":"R Weinlich","year":"2017","unstructured":"Weinlich R, Oberst A, Beere HM, Green DR. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol. 2017;18:127\u201336.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1691_CR89","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/ijms25021180","volume":"25","author":"SR Volovat","year":"2024","unstructured":"Volovat SR, et al. Oncolytic virotherapy: a new paradigm in cancer immunotherapy. Int J Mol Sci. 2024;25:1180.","journal-title":"Int J Mol Sci"},{"key":"1691_CR90","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/cr.2016.100","volume":"26","author":"X Chen","year":"2016","unstructured":"Chen X, et al. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 2016;26:1007\u201320.","journal-title":"Cell Res"},{"key":"1691_CR91","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41419-019-1441-4","volume":"10","author":"J Yu","year":"2019","unstructured":"Yu J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 2019;10:193.","journal-title":"Cell Death Dis"},{"key":"1691_CR92","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathmechdis-032221-115501","volume":"17","author":"L Maiorino","year":"2022","unstructured":"Maiorino L, Da\u00dfler-Plenker J, Sun L, Egeblad M. Innate immunity and cancer pathophysiology. Annu Rev Pathol. 2022;17:425\u201357.","journal-title":"Annu Rev Pathol"},{"key":"1691_CR93","doi-asserted-by":"crossref","first-page":"64534","DOI":"10.18632\/oncotarget.17885","volume":"8","author":"S-J He","year":"2017","unstructured":"He S-J, et al. The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget. 2017;8:64534\u201350.","journal-title":"Oncotarget"},{"key":"1691_CR94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cytogfr.2020.07.007","volume":"56","author":"LA Santry","year":"2020","unstructured":"Santry LA, et al. Tumour vasculature: friend or foe of oncolytic viruses? Cytokine Growth Factor Rev. 2020;56:69\u201382.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1691_CR95","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/mt.2015.233","volume":"24","author":"A Tedcastle","year":"2016","unstructured":"Tedcastle A, Illingworth S, Brown A, Seymour LW, Fisher KD. Actin-resistant DNAse I expression from oncolytic adenovirus enadenotucirev enhances its intratumoral spread and reduces tumor growth. Mol Ther. 2016;24:796\u2013804.","journal-title":"Mol Ther"},{"key":"1691_CR96","doi-asserted-by":"crossref","first-page":"e008431","DOI":"10.1136\/jitc-2023-008431","volume":"12","author":"S Wang","year":"2024","unstructured":"Wang S, Li Y, Xu C, Dong J, Wei J. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy. J Immunother Cancer. 2024;12:e008431.","journal-title":"J Immunother Cancer"},{"key":"1691_CR97","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-023-01442-3","volume":"8","author":"M You","year":"2023","unstructured":"You M, et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8:196.","journal-title":"Signal Transduct Target Ther"},{"key":"1691_CR98","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/15548627.2021.1990515","volume":"18","author":"Y Gong","year":"2022","unstructured":"Gong Y, et al. Newcastle disease virus degrades SIRT3 via PINK1-PRKN-dependent mitophagy to reprogram energy metabolism in infected cells. Autophagy. 2022;18:1503\u201321.","journal-title":"Autophagy"},{"key":"1691_CR99","doi-asserted-by":"crossref","first-page":"1525940","DOI":"10.3389\/fonc.2024.1525940","volume":"14","author":"M Zhou","year":"2024","unstructured":"Zhou M, Shen Z. Advanced progress in the genetic modification of the oncolytic HSV-1 virus. Front Oncol. 2024;14:1525940.","journal-title":"Front Oncol"},{"key":"1691_CR100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2024.07.079","volume":"374","author":"N Shuwari","year":"2024","unstructured":"Shuwari N, et al. Small extracellular vesicles carrying reovirus, tumor antigens, interferon-\u03b2, and damage-associated molecular patterns for efficient tumor treatment. J Control Release. 2024;374:89\u2013102.","journal-title":"J Control Release"},{"key":"1691_CR101","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","volume":"9","author":"B Wang","year":"2024","unstructured":"Wang B, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9:200.","journal-title":"Signal Transduct Target Ther"},{"key":"1691_CR102","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.831091","volume":"9","author":"F Cristi","year":"2022","unstructured":"Cristi F, Guti\u00e9rrez T, Hitt MM, Shmulevitz M. Genetic modifications that expand oncolytic virus potency. Front Mol Biosci. 2022;9: 831091.","journal-title":"Front Mol Biosci"},{"key":"1691_CR103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-023-04817-w","volume":"22","author":"J Zhang","year":"2024","unstructured":"Zhang J, et al. Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer. J Transl Med. 2024;22:3.","journal-title":"J Transl Med"},{"key":"1691_CR104","doi-asserted-by":"crossref","first-page":"1324744","DOI":"10.3389\/fimmu.2023.1324744","volume":"14","author":"L Xu","year":"2023","unstructured":"Xu L, Sun H, Lemoine NR, Xuan Y, Wang P. Oncolytic vaccinia virus and cancer immunotherapy. Front Immunol. 2023;14:1324744.","journal-title":"Front Immunol"},{"key":"1691_CR105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/v15020308","volume":"15","author":"SC Anker","year":"2023","unstructured":"Anker SC, et al. Oncolytic measles virus encoding microrna for targeted RNA interference. Viruses. 2023;15:308.","journal-title":"Viruses"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01691-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:46:56Z","timestamp":1764917216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01691-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01691-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}